First Time Loading...

Tyme Technologies Inc
NASDAQ:TYME

Watchlist Manager
Tyme Technologies Inc Logo
Tyme Technologies Inc
NASDAQ:TYME
Watchlist
Price: 0.3107 USD 8.07%
Updated: Mar 29, 2024

Intrinsic Value

TYME price has not been updated for more than 4 months. This may indicate that the stock has been delisted.

Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. [ Read More ]

There is not enough data to reliably calculate the intrinsic value of TYME.

Key Points:
TYME Intrinsic Value
Base Case
Not Available
Base Case Scenario

Fundamental Analysis

How can I assist you today?

Provide an overview
of Tyme Technologies Inc's business.

What risks and challenges
does Tyme Technologies Inc face in the near future?

Summarize the latest earnings report
of Tyme Technologies Inc.

Provide P/E
for Tyme Technologies Inc and its competitors.

Financials

Balance Sheet Decomposition
Tyme Technologies Inc

Current Assets 79m
Cash & Short-Term Investments 77.1m
Other Current Assets 1.9m
Non-Current Assets 1.1m
Long-Term Investments 1.1m
PP&E 28.2k
Current Liabilities 5.6m
Accrued Liabilities 491.6k
Other Current Liabilities 5.1m
Non-Current Liabilities 400.9k
Other Non-Current Liabilities 400.9k
Efficiency

Earnings Waterfall
Tyme Technologies Inc

Revenue
0 USD
Operating Expenses
-25.5m USD
Operating Income
-25.5m USD
Other Expenses
1.3m USD
Net Income
-24.2m USD

Free Cash Flow Analysis
Tyme Technologies Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

TYME Profitability Score
Profitability Due Diligence

Tyme Technologies Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

31/100
Profitability
Score

Tyme Technologies Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

TYME Solvency Score
Solvency Due Diligence

Tyme Technologies Inc's solvency score is 52/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
52/100
Solvency
Score

Tyme Technologies Inc's solvency score is 52/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TYME Price Targets Summary
Tyme Technologies Inc

There are no price targets for TYME.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

TYME Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

TYME Price
Tyme Technologies Inc

1M 1M
-
6M 6M
-
1Y 1Y
-
3Y 3Y
-81%
5Y 5Y
-82%
10Y 10Y
-94%
Annual Price Range
0.3107
52w Low
N/A
52w High
N/A
Price Metrics
Average Annual Return -12.48%
Standard Deviation of Annual Returns 9.68%
Max Drawdown -94%
Shares Statistics
Market Capitalization 53.5m USD
Shares Outstanding 172 207 008
Percentage of Shares Shorted 0.59%

TYME Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Tyme Technologies Inc Logo
Tyme Technologies Inc

Country

United States of America

Industry

Biotechnology

Market Cap

53.5m USD

Dividend Yield

0%

Description

Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. The company is headquartered in Bedminster, New Jersey and currently employs 17 full-time employees. The company went IPO on 2012-05-25. The firm is focused on developing cancer metabolism-based therapies (CMBTs) for a range of solid tumors and hematologic cancers. The firm's lead clinical CMBT compound, SM-88, is an oral investigational modified tyrosine derivative that is hypothesized to interrupt the metabolic processes of cancer cells by breaking down the cell's key defenses and leading to cell death through oxidative stress and exposure to the body's natural immune system. The company is also developing SM-88i, an injectable formulation of SM-88 for the treatment of multiple oncology indications. Its TYME-18, is a pre-clinical CMBT designed for the intra-tumoral delivery of the treatment and increase the permeability of cancer cells, while delivering a therapy having selective cytotoxic effect on the tumor. Its TYME-19, is an oral, synthetically produced member of the bile acid family that is being developed for the potential treatment of COVID-19.

Contact

NEW JERSEY
Bedminster
1 Pluckemin Way - Suite 103
+12124612315.0
https://www.tymeinc.com/

IPO

2012-05-25

Employees

17

Officers

CEO & Director
Mr. Richard Cunningham
Co-Founder & Director
Mr. Steven E. Hoffman
Chief Financial Officer
Mr. Frank L. Porfido
Chief Legal Officer & Sec.
Mr. James Biehl J.D.
Chief Bus. Officer
Dr. Jonathan M. Eckard
Acting Chief Medical Officer
Dr. Jan Marie-Albert Van Tornout M.D., M.Sc.

See Also

Discover More